DDInter1846 DDInter1676
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER-2 protein in tumours. It is suggested that the overexpression or gene amplification of HER2 has been found in about 20–30% of breast cancers and elevated activation of HER2 triggers multiple downstream pathways leading to abnormal proliferation of cancer cells. Trastuzumab binds to HER2 and suppresses cancer cell growth, proliferation, and survival directly and indirectly. In December 2017, FDA approved OGIVRI (
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Trastuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Trastuzumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Trastuzumab may lead to a major life threatening interaction when taken with Deferiprone
Trastuzumab may lead to a major life threatening interaction when taken with Etanercept